NL-OMON42613
Completed
Not Applicable
A phase I study to investigate the pharmacokinetics, safety and tolerability of four different dosing regimens of GRC 17536 in healthy male volunteers using tablet formulation. - GRC 17536 multiple dose study in healthy volunteers.
Glenmark Pharmaceuticals SA0 sites28 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pijn en luchtwegaandoeningen
- Sponsor
- Glenmark Pharmaceuticals SA
- Enrollment
- 28
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •healthy male subjects
- •18 \- 45 years of age, inclusive
- •BMI 18\.0 \- 28\.0 kilograms/meter2, inclusive
- •weight at least 50 kilograms
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A single-center study of the safety, tolerability and pharmacokinetics of a single concentration of topical SM04554 (0.25% concentration) solution in male subjects with androgenetic alopecia.Androgenetic alopecia (AGA)Skin - Dermatological conditionsMetabolic and Endocrine - Other endocrine disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12615000980538Samumed Pacific Pty Ltd25
Active, not recruiting
Phase 1
A Phase I study to investigate the pharmacokinetics and ECG effects of two single ascending doses of linaprazan glurate given as oral tablets to healthy subjectsErosive Gastroesophageal Reflux Disease (eGERD)MedDRA version: 20.1Level: LLTClassification code: 10017924Term: Gastroesophageal reflux Class: 10017947Therapeutic area: Diseases [C] - Digestive System Diseases [C06]CTIS2024-516261-36-00Cinclus Pharma Holding AB (publ)63
Recruiting
Phase 1
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620001261909Ascil Australia Pty LTD16
Completed
Phase 1
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620000108910Ascil Australia Pty Ltd8
Recruiting
Phase 1
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90